Vertex Pharmaceuticals stock slips to EUR 487.60, down 1.28%
Published on 11/17/2026 at 08:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFDA review sets late-November milestone
- Vertex raised 2026 revenue guidance to USD 13.15 billion to USD 13.25 billion after third-quarter revenue rose 12 percent to USD 3.44 billion.
- The FDA has set November 30, 2026, as the target action date for povetacicept in IgA nephropathy.
- Management said at a UBS investor event on November 16 that Vertex is prepared to launch the treatment if approved.
Vertex Pharmaceuticals stock traded at EUR 487.60 on Lang & Schwarz at 08:50 CET on Tuesday, November 17, 2026, 1.28 percent below the Xetra close of EUR 493.90 on Monday, November 16.
The US biotechnology company is expanding beyond its cystic-fibrosis franchise with medicines for acute pain, blood disorders and kidney disease. Vertex reported third-quarter revenue of USD 3.44 billion, up 12 percent from a year earlier, and raised its 2026 revenue guidance to USD 13.15 billion to USD 13.25 billion, according to the Financial Times.
The next major date is November 30, when the US Food and Drug Administration has set a target action date for povetacicept in IgA nephropathy. The drug is under priority review. At a UBS investor event on November 16, management said Vertex is prepared to launch povetacicept if it receives approval, MarketBeat reported.
US healthcare shares will also trade within the broader S&P 500 market environment.
